Ilio Vitale

List of Publications by Year in Descending Order

122 papers	17,654 citations	49 h-index	131 g-index
131 ext. papers	21,172 ext. citations	9.3 avg, IF	6.26 L-index

#	Paper	IF	Citations
122	Using epigenetic modifiers to target cancer stem cell immunoevasion.. *Cancer Cell*, **2021**, 39, 1573-1575	24.3	3
121	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. *Cancers*, **2021**, 13,	6.6	4
120	BRIO: a web server for RNA sequence and structure motif scan. *Nucleic Acids Research*, **2021**, 49, W67-W71	16.1	2
119	Oncosuppressive functions of PIDD1 in response to centrosome amplification. *Cell Death and Disease*, **2021**, 12, 175	9.8	
118	Intratumoral heterogeneity in cancer progression and response to immunotherapy. *Nature Medicine*, **2021**, 27, 212-224	50.5	84
117	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. *Cell Death and Differentiation*, **2021**, 28, 2060-2082	12.7	10
116	Relative Information Gain: Shannon entropy-based measure of the relative structural conservation in RNA alignments. *NAR Genomics and Bioinformatics*, **2021**, 3, lqab007	3.7	3
115	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death **2020**, 8,		233
114	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. *Methods in Enzymology*, **2020**, 632, 39-54	1.7	
113	Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. *Nature Immunology*, **2020**, 21, 120-134	19.1	101
112	Caspase 2 and p53 Reunited in Tumor Control. *Trends in Cell Biology*, **2020**, 30, 917-918	18.3	
111	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. *Frontiers in Immunology*, **2020**, 11, 2166	8.4	19
110	Stress responses in stromal cells and tumor homeostasis. *Pharmacology & Therapeutics*, **2019**, 200, 55-68	13.9	17
109	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. *Trends in Cell Biology*, **2019**, 29, 396-416	18.3	37
108	Macrophages and Metabolism in the Tumor Microenvironment. *Cell Metabolism*, **2019**, 30, 36-50	24.6	374
107	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. *OncoImmunology*, **2018**, 7, e1457602	7.2	6
106	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation*, **2018**, 25, 486-541	12.7	2160

105	Everybody In! No Bouncers at Tumor Gates. *Trends in Genetics*, **2018**, 34, 85-87	8.5	2
104	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. *Gut*, **2018**, 67, 903-917	19.2	45
103	Replication stress response in cancer stem cells as a target for chemotherapy. *Seminars in Cancer Biology*, **2018**, 53, 31-41	12.7	23
102	Calcium signaling and cell cycle: Progression or death. *Cell Calcium*, **2018**, 70, 3-15	4	99
101	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. *International Journal of Cancer*, **2017**, 140, 2587-2595	7.5	21
100	Body mass index modifies the relationship between □H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. *BMC Cancer*, **2017**, 17, 101	4.8	11
99	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. *OncoImmunology*, **2017**, 6, e1314424	7.2	69
98	DNA Damage in Stem Cells. *Molecular Cell*, **2017**, 66, 306-319	17.6	172
97	Spontaneous DNA damage propels tumorigenicity. *Cell Research*, **2017**, 27, 720-721	24.7	3
96	Caspase 2 in mitotic catastrophe: The terminator of aneuploid and tetraploid cells. *Molecular and Cellular Oncology*, **2017**, 4, e1299274	1.2	17
95	Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases. *International Review of Cell and Molecular Biology*, **2017**, 328, 105-161	6	29
94	ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy. *Oncotarget*, **2017**, 8, 21692-21709	3.3	30
93	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. *Scientific Reports*, **2017**, 7, 8078	4.9	13
92	Driving to Cancer on a Four-Lane Expressway. *Trends in Genetics*, **2017**, 33, 491-492	8.5	5
91	Synchronization and Desynchronization of Cells by Interventions on the Spindle Assembly Checkpoint. *Methods in Molecular Biology*, **2017**, 1524, 77-95	1.4	2
90	Trial watch - inhibiting PARP enzymes for anticancer therapy. *Molecular and Cellular Oncology*, **2016**, 3, e1053594	1.2	18
89	LTX-315, CAPtivating immunity with necrosis. *Cell Cycle*, **2016**, 15, 1176-7	4.7	3
88	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. *PLoS ONE*, **2016**, 11, e0149872	3.7	8

87	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. *Oncotarget*, **2016**, 7, 885-901	5.5	23
86	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. *OncoImmunology*, **2016**, 5, e1160187	7.2	24
85	Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins. *Methods in Molecular Biology*, **2016**, 1417, 231-45	1.4	1
84	Trial Watch: Proteasomal inhibitors for anticancer therapy. *Molecular and Cellular Oncology*, **2015**, 2, e974463	1.2	15
83	Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. *Molecular and Cellular Oncology*, **2015**, 2, e1012976	1.2	95
82	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. *Annals of Oncology*, **2015**, 26, 2470-7	10.3	15
81	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. *Science*, **2015**, 350, 972-8	33.3	267
80	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. *Trends in Cancer*, **2015**, 1, 124-135	12.5	22
79	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death and Differentiation*, **2015**, 22, 58-73	12.7	643
78	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. *Expert Reviews in Molecular Medicine*, **2015**, 17, e14	6.7	55
77	Role of autophagy in the maintenance and function of cancer stem cells. *International Journal of Developmental Biology*, **2015**, 59, 95-108	1.9	30
76	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. *Oncotarget*, **2015**, 6, 42773-80	3.3	13
75	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. *OncoImmunology*, **2015**, 4, e988042	7.2	21
74	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 3020-5	11.5	47
73	Systems biology of cisplatin resistance: past, present and future. *Cell Death and Disease*, **2014**, 5, e1257	9.8	476
72	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. *Nature Medicine*, **2014**, 20, 1301-9	50.5	596
71	PARP and other prospective targets for poisoning cancer cell metabolism. *Biochemical Pharmacology*, **2014**, 92, 164-71	6	23
70	MCL-1 dependency of cisplatin-resistant cancer cells. *Biochemical Pharmacology*, **2014**, 92, 55-61	6	40

69	Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691	7.2	524
68	Trial Watch: Radioimmunotherapy for oncological indications. *OncoImmunology*, **2014**, 3, e954929	7.2	36
67	Chloroquine and hydroxychloroquine for cancer therapy. *Molecular and Cellular Oncology*, **2014**, 1, e29911	1.2	120
66	Predictive biomarkers for cancer therapy with PARP inhibitors. *Oncogene*, **2014**, 33, 3894-907	9.2	83
65	Characterization of novel MPS1 inhibitors with preclinical anticancer activity. *Cell Death and Differentiation*, **2013**, 20, 1532-45	12.7	72
64	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. *Cell Cycle*, **2013**, 12, 877-83	4.7	42
63	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. *Oncogene*, **2013**, 32, 4995-5004	9.2	80
62	Cytofluorometric assessment of cell cycle progression. *Methods in Molecular Biology*, **2013**, 965, 93-120	1.4	8
61	Prognostic value of LIPC in non-small cell lung carcinoma. *Cell Cycle*, **2013**, 12, 647-54	4.7	13
60	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. *OncoImmunology*, **2013**, 2, e22409	7.2	17
59	Cisplatin resistance associated with PARP hyperactivation. *Cancer Research*, **2013**, 73, 2271-80	10.1	123
58	Immunosurveillance against tetraploidization-induced colon tumorigenesis. *Cell Cycle*, **2013**, 12, 473-9	4.7	28
57	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. *Cell Cycle*, **2013**, 12, 417-21	4.7	24
56	Trial watch: Dendritic cell-based interventions for cancer therapy. *OncoImmunology*, **2013**, 2, e25771	7.2	87
55	Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations. *Cell Cycle*, **2013**, 12, 183-90	4.7	5
54	Trial Watch: Anticancer radioimmunotherapy. *OncoImmunology*, **2013**, 2, e25595	7.2	75
53	Impact of the Ku complex on HIV-1 expression and latency. *PLoS ONE*, **2013**, 8, e69691	3.7	19
52	Prognostic impact of vitamin B6 metabolism in lung cancer. *Cell Reports*, **2012**, 2, 257-69	10.6	100

51	Preferential killing of p53-deficient cancer cells by reversine. *Cell Cycle*, **2012**, 11, 2149-58	4.7	31
50	An immunosurveillance mechanism controls cancer cell ploidy. *Science*, **2012**, 337, 1678-84	33.3	299
49	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death and Differentiation*, **2012**, 19, 107-20	12.7	1843
48	Molecular mechanisms of cisplatin resistance. *Oncogene*, **2012**, 31, 1869-83	9.2	1567
47	Selective killing of p53-deficient cancer cells by SP600125. *EMBO Molecular Medicine*, **2012**, 4, 500-14	12	43
46	Autophagic removal of micronuclei. *Cell Cycle*, **2012**, 11, 170-6	4.7	130
45	Independent transcriptional reprogramming and apoptosis induction by cisplatin. *Cell Cycle*, **2012**, 11, 3472-80	4.7	31
44	Evaluation of rapamycin-induced cell death. *Methods in Molecular Biology*, **2012**, 821, 125-69	1.4	12
43	Mitochondrial liaisons of p53. *Antioxidants and Redox Signaling*, **2011**, 15, 1691-714	8.4	62
42	Past, present, and future of molecular and cellular oncology. *Frontiers in Oncology*, **2011**, 1, 1	5.3	16
41	Cell death signaling and anticancer therapy. *Frontiers in Oncology*, **2011**, 1, 5	5.3	36
40	Mitotic catastrophe: a mechanism for avoiding genomic instability. *Nature Reviews Molecular Cell Biology*, **2011**, 12, 385-92	48.7	556
39	Illicit survival of cancer cells during polyploidization and depolyploidization. *Cell Death and Differentiation*, **2011**, 18, 1403-13	12.7	102
38	Oncosuppressive functions of autophagy. *Antioxidants and Redox Signaling*, **2011**, 14, 2251-69	8.4	74
37	A fluorescence-microscopic and cytofluorometric system for monitoring the turnover of the autophagic substrate p62/SQSTM1. *Autophagy*, **2011**, 7, 883-91	10.2	31
36	Cytofluorometric purification of diploid and tetraploid cancer cells. *Methods in Molecular Biology*, **2011**, 761, 47-63	1.4	3
35	Viral strategies for the evasion of immunogenic cell death. *Journal of Internal Medicine*, **2010**, 267, 526-42	10.8	47
34	A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis. *Oncogene*, **2010**, 29, 5869-72	9.2	4

33	The IKK complex contributes to the induction of autophagy. *EMBO Journal*, **2010**, 29, 619-31	13	248
32	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. *EMBO Journal*, **2010**, 29, 1272-84	13	119
31	miR-181a and miR-630 regulate cisplatin-induced cancer cell death. *Cancer Research*, **2010**, 70, 1793-803	10.1	243
30	Involvement of p38 in the mitotic progression of p53-/- tetraploid cells. *Cell Cycle*, **2010**, 9, 2895-2901	4.7	5
29	Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells. *Cell Cycle*, **2010**, 9, 377-83	4.7	16
28	An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. *Cell Death and Disease*, **2010**, 1, e25	9.8	34
27	Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. *Cell Death and Disease*, **2010**, 1, e10	9.8	441
26	Mitochondrial gateways to cancer. *Molecular Aspects of Medicine*, **2010**, 31, 1-20	16.7	210
25	The life span-prolonging effect of sirtuin-1 is mediated by autophagy. *Autophagy*, **2010**, 6, 186-8	10.2	113
24	IKK connects autophagy to major stress pathways. *Autophagy*, **2010**, 6, 189-91	10.2	39
23	Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. *Cell Cycle*, **2009**, 8, 1030-5	4.7	37
22	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. *Cell Cycle*, **2009**, 8, 1380-5	4.7	35
21	A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. *Apoptosis: an International Journal on Programmed Cell Death*, **2009**, 14, 182-90	5.4	31
20	The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. *Cell Death and Differentiation*, **2009**, 16, 1006-17	12.7	235
19	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. *Cell Death and Differentiation*, **2009**, 16, 1093-107	12.7	533
18	Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. *Oncogene*, **2009**, 28, 4249-60	9.2	47
17	Disruption of the PP1/GADD34 complex induces calreticulin exposure. *Cell Cycle*, **2009**, 8, 3971-7	4.7	30
16	Regulation of autophagy by cytoplasmic p53. *Nature Cell Biology*, **2008**, 10, 676-87	23.4	899

15	Methods to dissect mitochondrial membrane permeabilization in the course of apoptosis. *Methods in Enzymology*, **2008**, 442, 355-74	1.7	21
14	Methods for assessing autophagy and autophagic cell death. *Methods in Molecular Biology*, **2008**, 445, 29-76	1.4	144
13	The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. *Cell Death and Differentiation*, **2008**, 15, 1499-509	12.7	253
12	Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. *Cell Cycle*, **2008**, 7, 1956-61	4.7	35
11	Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. *Cancer Research*, **2008**, 68, 5301-8	10.1	96
10	The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. *Apoptosis: an International Journal on Programmed Cell Death* , **2008**, 13, 659-69	5.4	40
9	Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. *PLoS ONE*, **2007**, 2, e1337	3.7	59
8	Regulation of autophagy by the inositol trisphosphate receptor. *Cell Death and Differentiation*, **2007**, 14, 1029-39	12.7	274
7	Cell death modalities: classification and pathophysiological implications. *Cell Death and Differentiation*, **2007**, 14, 1237-43	12.7	581
6	Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. *Apoptosis: an International Journal on Programmed Cell Death*, **2007**, 12, 155-66	5.4	46
5	Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. *Cell Cycle*, **2007**, 6, 2263-7	4.7	106
4	Depletion of endonuclease G selectively kills polyploid cells. *Cell Cycle*, **2007**, 6, 1072-6	4.7	26
3	Apoptosis regulation in tetraploid cancer cells. *EMBO Journal*, **2006**, 25, 2584-95	13	153
2	Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. *Annals of the New York Academy of Sciences*, **2006**, 1090, 35-49	6.5	43
1	Caspase-independent apoptosis is activated by diazepam-induced mitotic failure in HeLa cells, but not in human primary fibroblasts. *Apoptosis: an International Journal on Programmed Cell Death*, **2005**, 10, 909-20	5.4	12